Replies to post #123024 on Biotech Values

[oc631]

Do you know what part of the GT2/3 patients population get a shorter 16 weeks course (depending on having low baseline viral load and perhaps RVR)?

Roche was unable to shorten the treatment duration in their ACCELERATE trial. 16 weeks of treatment with SOC saw lower SVR rates and higher relapse rates. As far as I know 24 weeks of treatment is the standard.